



Keith Houck, Ph.D.

Dr. Keith Houck is with the EPA's National Center for Computational Toxicology. As part of the Tox21 collaboration between EPA, NIH and FDA, he leads efforts to develop and apply *in vitro* methods for predicting potential for chemical toxicity. Prior to joining the EPA in 2006, Dr. Houck worked in the biotechnology and pharmaceutical fields where he applied molecular and cellular biology skills towards identification of drug candidates for Sphinx Pharmaceuticals and Eli Lilly & Co. Earlier, he completed a postdoctoral fellowship at Genentech, Inc., in the molecular biology department following receiving his PhD in Pathology and Toxicology from Duke University in 1989. Prior to that, he received an MS in Chemistry from the University of North Carolina at Chapel Hill and BS in Biology from Guilford College.